Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$8.11 ▼ -0.31
(-3.68%)
MKT CAP: $73.1M • VOL: 33.0K
52W L $4 52W H $13
ROARABLE / RQD
D- • 38/100
PIOTROSKI
4 / 9
ECOR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $32.0M | $25.2M | $16.0M |
| YoY Revenue Growth % | +27.2% | +57.1% | — |
| Gross Profit | $27.8M | $21.4M | — |
| Gross Margin % | 86.8% | 85.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$13.2M | -$12.2M | -$19.3M |
| Operating Margin % | -41.1% | -48.3% | -80.0% |
| Net Income (GAAP) | -$14.0M | -$11.9M | -$18.8M |
| EBITDA (Normalized) | -$13.1M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.2M | -$6.9M | -$14.7M |
| Capital Expenditures (CapEx) | $66.0K | — | — |
| Free Cash Flow (FCF) | -$8.3M | -$6.9M | -$14.7M |
| FCF Margin % | -25.8% | -27.6% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.0M | $3.7M | — |
| Total Debt (Short + Long Term) | $6.6M | — | — |
| Total Stockholders' Equity | -$1.7M | $7.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ECOR.